The patent, number 7,897,080, covers the combination of polymers like include carboxymethylcellulose, hydroxyethyl cellulose polyethylene oxide with actives such as buprenorphine, ondansetron, fentanyl and triptan.
CEO Mark Schobel claimed that the award makes MonoSol RX the leader in the pharmaceutical film sector and gives the firm “process protection for the manufacturing of single and multi-layer films delivering a wide range of drug classifications through buccal and sublingual administration."
The award follows just over a year after MonoSol received its last patent that covered a nanoparticle film drug delivery system for administering biologics.